0. DOCID:26937 SCORE: 0.00354798978123113
DOCNO: 10940507
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Polymorphism, Genetic
QUALIFIER: genetics
QUALIFIER: genetics
AUTHOR: I Saadat I
AUTHOR: M Saadat M
AFFILIATION: Department of Biology, College of Sciences, Shiraz University, 71454, Shiraz, Iran.
PUBTYPE: Journal Article
JOURNALTITLE: Cancer letters.
COUNTRY: IRELAND
TITLE: The glutathione S-transferase mu polymorphism and susceptibility to acute lymphocytic leukemia.
PUBDATE: 20000901
It has been postulated that the absence of glutathione S-transferase mu (GSTmu), which impairs detoxification of some carcinogens, might predispose some individuals to the development of certain cancers. In the present study, polymorphism of GSTM1 were detected by polymerase chain reaction (PCR) in 38 patients with acute lymphocytic leukemia and 75 normal subjects. The null genotype of GSTM1 was significantly more common among leukemic patients compared with the normal control group (55.3 vs. 32.0%; P<0.025). The absence of the GSTmu enzyme may increase the risk of the development of leukemia.


1. DOCID:24724 SCORE: 0.00286846808172891
DOCNO: 10860214
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Double Effect
DESCRIPTOR: Ethics
DESCRIPTOR: Ethics, Medical
DESCRIPTOR: Intention
QUALIFIER: legislation & jurisprudence
QUALIFIER: legislation & jurisprudence
AUTHOR: C E Kendall CE
AFFILIATION: St Peter's Hospice, Bristol.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Journal of medical ethics.
COUNTRY: ENGLAND
TITLE: At the coalface: medical ethics in practice. A double dose of double effect.
PUBDATE: 20000601
This paper presents a clinically orientated illustration of the doctrine of double effect. The case of an elderly gentleman with advanced cancer is discussed, with particular emphasis on two dilemmas encountered during the terminal phase of his illness. The author describes how the doctrine of double effect was applied to help the team make some complex management decisions.


2. DOCID:27319 SCORE: 0.00265910832642292
DOCNO: 10448183
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapy
AUTHOR: J Moppett J
AUTHOR: I Haddadin I
AUTHOR: A B Foot AB
AFFILIATION: The Royal Hospital for Sick Children St Michael's Hill Bristol BS2 8BJ.
PUBTYPE: Journal Article
JOURNALTITLE: Archives of disease in childhood. Fetal and neonatal edition.
COUNTRY: ENGLAND
TITLE: Neonatal neuroblastoma.
PUBDATE: 19990901
Over nine years, 33 children with neonatal neuroblastoma were registered with the UKCCSG (United Kingdom Children's Cancer Study Group). Tumours of all stages were found, but stage 4S disease predominated. Five tumours were detected prenatally by ultrasonography. Treatment varied according to tumour stage. The overall survival of the group was 91%. Ten children have had long term complications as a result of their disease, usually as a result of spinal tumour involvement. The good overall prognosis in this age group is encouraging, but the poor neurological outcome of patients with intraspinal extension is of concern.


3. DOCID:27232 SCORE: 0.00265910785423408
DOCNO: 14659026
OWNER: NLM
STATUS: PubMed-not-MEDLINE
AUTHOR: C P Schultheis CP
AUTHOR: M A Raheem MA
AUTHOR: M C Perry MC
AFFILIATION: University of Missouri/Ellis Fischel Cancer Center, Columbia, Missouri 65203, USA.
PUBTYPE: Journal Article
JOURNALTITLE: Clinical lung cancer.
COUNTRY: United States
TITLE: Second-line chemotherapy for small-cell lung cancer: a review.
PUBDATE: 20011101
Small-cell lung cancer (SCLC) is an aggressive malignancy, and only a minority of patients survive 2 years. Although this cancer is sensitive to both chemotherapy and radiotherapy, the majority of patients relapse, and second-line treatment is an option for many. Currently in the United States, the combination of cisplatin/etoposide is the standard first-line therapy in SCLC. At this time, topotecan is the only Food and Drug Administration-approved chemotherapeutic agent for second-line treatment of SCLC. In this paper, we review studies of second-line chemotherapy for SCLC.


4. DOCID:26694 SCORE: 0.00258279236426558
DOCNO: 11249681
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: pharmacology
QUALIFIER: genetics
QUALIFIER: pharmacology
AUTHOR: G Forni G
AUTHOR: K Boggio K
AFFILIATION: Department of Clinical and Biological Sciences, University of Turin, Ospedale San Luigi Gonzaga, 10043 Orbassano, Italy. forni@pasteur.sluigi.unito.it
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in molecular therapeutics.
COUNTRY: England
TITLE: Cytokine gene-engineered vaccines.
PUBDATE: 19990201
Cytokines modulate immune reactivity and have therefore been used to build cancer vaccines. Experimental vaccination of rodents and humans with cytokine-gene engineered tumor cells, fusion proteins between cytokines and tumor antigens, and their DNA have been shown to induce a significant immune memory, even against poorly immunogenic tumors. This immune memory can prevent tumor growth and cure initial metastases, but is poorly effective against established tumors. To date clinical trials have been confined to patients with advanced tumors; so far they suggest that this approach is safe.


5. DOCID:27938 SCORE: 0.00253207957635948
DOCNO: 10431670
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: adverse effects
QUALIFIER: prevention & control
AUTHOR: E M McCarthy EM
AUTHOR: K P Ethridge KP
AUTHOR: R F Wagner RF
AFFILIATION: Department of Dermatology, University of Texas Medical Branch, Galveston 77555-0783, USA.
PUBTYPE: Journal Article
JOURNALTITLE: Cutis; cutaneous medicine for the practitioner.
COUNTRY: UNITED STATES
TITLE: Beach holiday sunburn: the sunscreen paradox and gender differences.
PUBDATE: 19990701
A survey about sunbathing practices was performed on a summer holiday weekend at a Galveston beach. The likelihood of sunburn increased with increasing duration of sun exposure, with 100% of subjects experiencing sunburn after exposure > or = 4.5 hours. Men exhibited a significantly higher frequency of sunburn, employed fewer sun-protective measures, and demonstrated less knowledge concerning sun safety information and skin cancer than women. This information suggests a need for greater educational efforts directed toward changing public attitudes about preventing sunburn, especially those of men, that currently lead to high-risk sunbathing behavior.


6. DOCID:27955 SCORE: 0.00238011860725909
DOCNO: 9656791
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: etiology
QUALIFIER: metabolism
QUALIFIER: physiology
AUTHOR: T I Andersen TI
AFFILIATION: Avdeling for medisinsk genetikk UllevÄl sykehus, Blindern, Oslo.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Tidsskrift for den Norske laegeforening.
COUNTRY: NORWAY
TITLE: [Telomeres, telomerase and development of cancer]
PUBDATE: 19980501
The chromosome ends, telomeres, shorten during each cell division due to the inability of DNA polymerase to replicate the ends of linear chromosomes. The telomere length serves as a clock determining the remaining replicative capacity of the cell. After 50-100 doublings, the cell becomes senescent. Rarely, a cell overcomes the senescence blockade, and eventually becomes immortal. Cellular immortalisation is almost always accompanied by the expression of the enzyme telomerase, which synthesises telomeric DNA. Telomerase is present in approximately 85% of malignancies. The detection of telomerase activity in cancer cells represents a possible cancer diagnostic and prognostic tool, and telomerase inhibition may become a novel therapeutic strategy in cancer patients.


7. DOCID:26567 SCORE: 0.00226593597373778
DOCNO: 11354372
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: chemical synthesis
QUALIFIER: pharmacology
QUALIFIER: chemical synthesis
QUALIFIER: pharmacology
QUALIFIER: chemical synthesis
QUALIFIER: pharmacology
AUTHOR: F M Uckun FM
AUTHOR: C J Forsyth CJ
AFFILIATION: Parker Hughes, Cancer Center, Department of Oncology and Drug Discovery Program, Parker Hughes Institute, St. Paul, MN 55113, USA. faith_uckun@ih.org
PUBTYPE: Journal Article
JOURNALTITLE: Bioorganic & medicinal chemistry letters.
COUNTRY: England
TITLE: Anticancer activity of synthetic analogues of the phorboxazoles.
PUBDATE: 20010501
The phorboxazoles are recently described natural products that are extremely cytostatic towards the National Cancer Institute's panel of 60 tumor cell lines. We report here the results of preliminary structure-activity studies of synthetic analogues of the phorboxazoles against BT-20 breast cancer, NALM-6 B-lineage ALL, U373 brain tumor, and U373 glioblastoma cell lines. These data indicate the importance of several of the natural products' structural moieties for potent anticancer activity.


8. DOCID:26846 SCORE: 0.0022657190910022
DOCNO: 11019375
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: complications
QUALIFIER: etiology
QUALIFIER: etiology
QUALIFIER: complications
AUTHOR: T Abe T
AUTHOR: S Konari S
AUTHOR: W Obara W
AUTHOR: T Okamoto T
AUTHOR: T Fujioka T
AFFILIATION: Department of Urology, Iwate Prefectual Senmaya Hospital.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Hinyokika kiyo. Acta urologica Japonica.
COUNTRY: JAPAN
TITLE: [A case of squamous cell carcinoma arising in the urinary bladder diverticulum]
PUBDATE: 20000801
A 49-year-old man was admitted to our hospital with the chief compliant of difficulty of urination, lower abdominal pain and macrohematuria. On cystoscopy, a non-papillary tumor was seen in the diverticulum on the right side of the urinary bladder. Having made the diagnosis of urinary bladder cancer, we performed total cystectomy, retroperitoneal node dissection and construction of an ileal neobladder. Histologically, it was squamous cell carcinoma, pT3a, pN0. Seven months after the operation, the patient died of recurrent disease.


9. DOCID:25543 SCORE: 0.00224102317589865
DOCNO: 10365264
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Pneumonectomy
QUALIFIER: surgery
AUTHOR: T W James TW
AUTHOR: L P Faber LP
AFFILIATION: Department of Cardiovascular and Thoracic Surgery, Rush Medical College, Chicago, Illinois, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Chest surgery clinics of North America.
COUNTRY: UNITED STATES
TITLE: Indications for pneumonectomy. Pneumonectomy for malignant disease.
PUBDATE: 19990501
The anatomic extent of a pulmonary malignancy usually dictates the need for pneumonectomy to achieve a complete resection. The requirement for a pneumonectomy can frequently be predicted by accurate clinical staging, but may also be required due to intraoperative findings relating to tumor invasion or nodal spread. Completion pneumonectomy is usually reserved for locally recurrent lung cancer or early to late complications following pulmonary resection. Malignant involvement of the carina frequently requires sleeve pneumonectomy.


10. DOCID:26156 SCORE: 0.00207647451676298
DOCNO: 10322156
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Epitopes, T-Lymphocyte
DESCRIPTOR: Immunotherapy, Adoptive
QUALIFIER: immunology
AUTHOR: L Chen L
AFFILIATION: Department of Immunology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota, 55905, USA. chen.lieping@mayo.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in immunology.
COUNTRY: ENGLAND
TITLE: Mimotopes of cytolytic T lymphocytes in cancer immunotherapy.
PUBDATE: 19990401
Rapid identification of the cytolytic T lymphocyte (CTL) epitopes that are presented by cancer cells will provide the basis for manipulation of tumor immunity but remains a major challenge in the field. By screening randomly synthesized peptide libraries, mimotopes for tumor-reactive CTLs can be readily constructed and they may be functionally equal to or potentially more potent than natural peptides in stimulating CTL responses; therefore, the peptide library approach provides great promise for design of cancer vaccines and adoptive tumor immunotherapy.


11. DOCID:24559 SCORE: 0.00199479021906575
DOCNO: 9700305
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: analysis
QUALIFIER: immunology
QUALIFIER: analysis
AUTHOR: K Brasso K
AUTHOR: P Skaarup P
AUTHOR: J U Roosen JU
AUTHOR: P Iverson P
AFFILIATION: H:S Rigshospitalet, kirurgisk afdeling D.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Ugeskrift for laeger.
COUNTRY: DENMARK
TITLE: [Use of prostate specific antigen. A review]
PUBDATE: 19980701
Since it was first introduced, measurement of prostate specific antigen has gained increasing interest, and prostate specific antigen is regarded as being the best tumour marker available. The antigen lacks cancer specificity, limiting the usefulness in early diagnosis, The use of prostate specific antigen in early diagnosis, staging, and in monitoring patients with prostate cancer is reviewed.


12. DOCID:27021 SCORE: 0.00193215366994429
DOCNO: 11458578
AUTHOR: M A Quinn MA
AFFILIATION: Melbourne University, Victoria. michael.quinn@hcoa.maynick.com.au
PUBTYPE: Journal Article
JOURNALTITLE: Australian family physician.
COUNTRY: Australia
TITLE: Screening for ovarian cancer.
PUBDATE: 20010601
BACKGROUND: Ovarian cancer is the leading cause of death from gynaecological malignancy, with over 800 Australian women dying annually, primarily because of late presentation of disease. Although a screening test for this disease is attractive, currently none are available for use in the general population. Work is underway in relation to the benefit for women at 'higher risk'. OBJECTIVE: To provide clear guidelines for screening for ovarian cancer. DISCUSSION: No single test currently has the sensitivity or specificity to be used as a population screening test for this disease. Nonetheless, for patients at 'high risk' the use of Ca125 and transvaginal ultrasound may be of benefit. Results from three major international multicentre trials are awaited.


13. DOCID:26791 SCORE: 0.00185972739648765
DOCNO: 9624217
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Gene Targeting
QUALIFIER: methods
QUALIFIER: therapy
AUTHOR: B M Clary BM
AUTHOR: H K Lyerly HK
AFFILIATION: Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Surgical oncology clinics of North America.
COUNTRY: UNITED STATES
TITLE: Transcriptional targeting for cancer gene therapy.
PUBDATE: 19980701
Novel treatment strategies incorporating gene transfer technology represent a new frontier in the treatment of cancer made possible through recent developments in molecular biology. Targeting of gene therapy strategies that rely on in situ gene modifications can theoretically occur at the gene entry or gene expression level. Regulation of gene transcription is made possible through the incorporation of cell-specific promoter and enhancer sequences within the transgene construct. This article provides a brief review of transcriptional processes and a description of the most widely studied cell-specific regulatory elements.


14. DOCID:25029 SCORE: 0.00180496844440811
DOCNO: 10921333
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Beckwith-Wiedemann Syndrome
DESCRIPTOR: Potassium Channels, Voltage-Gated
AUTHOR: K Yoshiura K
AUTHOR: N Niikawa N
AFFILIATION: Nagasaki University School of Medicine, Department of Human Genetics.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nippon rinsho. Japanese journal of clinical medicine.
COUNTRY: JAPAN
TITLE: [Beckwith-Wiedemann syndrome]
PUBDATE: 20000701
Beckwith-Wiedemann syndrome(BWS) is one of the most common overgrowth syndrome and is believed that imprinted genes contribute to the phenotypes of syndrome. Embryonic tumors are observed in 7.5%-10.0% of BWS, so BWS could be classified in one of the familial cancer syndrome. We describe here the causative mechanisms of BWS, mechanisms of tumorigenesis related to the BWS, and what to be uncovered in the next step.